Stock 600422 KPC PHARMACEUTICALS,INC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings KPC Pharmaceuticals,Inc

Equities

600422

CNE0000015P8

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-02 pm EDT 		5-day change 1st Jan Change
20.69 CNY +2.58% Intraday chart for KPC Pharmaceuticals,Inc -8.49% -0.81%
Apr. 19 KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 17 Kunyao Group Receives Clinical Trial Approval for FMF Drug MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The firm trades with high earnings multiples: 25.99 times its 2024 earnings per share.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
KPC PHARMACEUTICALS,INC Stock KPC Pharmaceuticals,Inc
-0.81% 2.11B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.60% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.34% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.74% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.79% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.37% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.47% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.26% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 206B
A+
AMGEN INC. Stock Amgen Inc.
+6.74% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600422 Stock
  4. Ratings KPC Pharmaceuticals,Inc